ReviewAging2012
Metformin in obesity, cancer and aging: addressing controversies.
Review in Aging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.Age (Dordrecht, Netherlands) · 2016Trial
- From Metabolism to Longevity: Molecular Mechanisms Underlying Metformin's Anticancer and Anti-Aging Effects.Current issues in molecular biology · 2026Review
- Molecular mechanisms of metformin action: From metabolic effects to lifespan extension and healthspan promotion.Journal of medical biochemistry · 2026Article
- White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions.Cancer metastasis reviews · 2022Review
- Metformin Attenuates Inflammatory Responses and Enhances Antibody Production in an Acute Pneumonia Model ofFrontiers in aging · 2022Article
- Inhibitory Action of Antidiabetic Drugs on the Free Radical Production by the Rod Outer Segment Ectopic Aerobic Metabolism.Antioxidants (Basel, Switzerland) · 2020Article
- Metformin improves boar sperm quality via 5'-AMP-activated protein kinase-mediated energy metabolismZoological research · 2020Article
- Transcriptomic landscape profiling of metformin-treated healthy mice: Implication for potential hypertension risk when prophylactically used.Journal of cellular and molecular medicine · 2020Article
- Understanding Drug Repurposing From the Perspective of Biomedical Entities and Their Evolution: Bibliographic Research Using Aspirin.JMIR medical informatics · 2020Article
- Rationale and Study Design of a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults With Prediabetes.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020Article
- Downregulation of IL-18 Expression in the Gut by Metformin-induced Gut Microbiota Modulation.Immune network · 2019Article
- Long-Term Moderate Exercise Combined with Metformin Treatment Induces an Hormetic Response That Prevents Strength and Muscle Mass Loss in Old Female Wistar Rats.Oxidative medicine and cellular longevity · 2019Article
- Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases.Molecules (Basel, Switzerland) · 2017Review
- From rapalogs to anti-aging formula.Oncotarget · 2017Review
- Article
- Metformin: A Hopeful Promise in Aging Research.Cold Spring Harbor perspectives in medicine · 2016Review
- Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.Scientific reports · 2016Article
- Metformin Treatment Prevents Sedentariness Related Damages in Mice.Journal of diabetes research · 2016Article
- When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?Current pharmacology reports · 2015Article
- Metformin for cancer and aging prevention: is it a time to make the long story short?Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan. Gradually accumulating discrepancies about its effect on cancer and obesity can be explained by the shortage of randomized clinical trials, differences between control groups (reference points), gender- and age-associated effects and pharmacogenetic factors. Studies of the potential antiaging effects of antidiabetic biguanides, such as metformin, are still experimental for obvious reasons and their results are currently ambiguous. Here we discuss whether the discrepancies in different studies are merely methodological or inherently related to individual differences in responsiveness to the drug.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.